Dispute Resolution Upholds FDA Request For New CIP-Isotretinoin Study From Cipher
This article was originally published in The Pink Sheet Daily
Executive Summary
Canadian firm is considering its options, CEO says.
You may also be interested in...
Cipher Seeks Meeting With FDA To Discuss Tramadol “Approvable” Letter
Agency asks for additional efficacy trial for the extended-release opioid analgesic.
Cipher To Appeal “Approvable” Letter for CIP-Isotretinoin
Toronto firm maintains agency’s request for additional clinical data has already been addressed in existing NDA package.
Cipher Seeks Marketing Partner For Fenofibrate Capsules
Approval of Lipofen through the 505(b)(2) pathway is the company’s first.